Summary:
A Phase 2, Randomized, Double-Blind, Active- and Placebo-controlled Trial of the safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit /Hyperactivity Disorder
Qualified Participants Must:
Be 18-55 years old and be diagnosed with ADHD
Qualified Participants May Receive:
Compensation for time and travel. Participants may receive investigational medication or placebo.